Objective The objective of this research was to describe the use of pharmacist-managed
sacubitril/valsartan therapy in a multi-center, outpatient cardiac group. Background …

Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization | Circulation Science
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

Abstract Background The LIFE (LCZ696 In Hospitalized Advanced Heart FailurE) trial, which
evaluated sacubitril/valsartan in patients with advanced heart failure (HF) with reduced …

Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in
patients with New York Heart Association class IV heart failure with a reduced ejection …

Sacubitril/valsartan was approved by the Food and Drug Administration in 2015 to reduce
the risk of cardiovascular death and hospitalization for heart failure (HHF) in patients with …

Randomized controlled trials (RCTs) of sacubitril/valsartan have suggested possible clinical
benefit among patients with heart failure with preserved ejection fraction (HFpEF). The …

Background The combination drug sacubitril/valsartan was reported to be superior to
enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical condition
characterized by large pathophysiology heterogeneity with lack of effective therapies as …

Aims This study aims to investigate the eligibility of the Prospective Comparison of
Angiotensin Receptor–Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on …